Skip to main content
. 2022 May 21;129(2):182–188.e1. doi: 10.1016/j.anai.2022.05.014

Table 2.

Reported Allergic Reactions (N = 44)

Reported allergic reactions
 Antibiotic or antifungal 8 (18.2%)
 Anti-inflammatory 3 (6.8%)
 Neurologic agents 1 (2.3%)
 Chemotherapy agent 1 (2.3%)
 Vaccine 5 (11.4%)
 Drug that contains similar ingredients as the COVID-19 vaccine 4 (9.1%)
 SARS-CoV-2 vaccine 40 (90.9%)
Latency of allergic reaction
Less than 6 mo 37 (84.1%)
More than 6 mo 7 (15.9%)
Reported symptoms
Dermatologic 28 (63.6%)
Respiratory 24 (54.5%)
Cardiovascular 11 (25%)
Gastrointestinal 4 (9.1%)
Time between exposure to allergen and reported reactions
 Less than 1 h 31 (70.4%)
 More than 1 h 13 (29.5%)
Hospitalization for the allergic episode
 ICU
3 (6.8%)
1 (33.3%)
Treatment administered
 Epinephrine 9 (20.5%)
 Antihistamines 36 (81.8%)
 Inhalers 1 (2.3%)
 Cortisone 7 (15.9%)
 Intravenous fluids 2 (4.5%)
 No treatment 6 (13.6%)
 Do not know 1 (2.3%)

Abbreviations: COVID-19, coronavirus disease 2019; FAAN, Food Allergy and Anaphylaxis Network; ICU, intensive care unit; NIAID, National Institute of Allergy and Infectious Diseases; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Latency: time between the reaction and the allergy evaluation.